Xenon Pharmaceuticals Future Growth
Future criteria checks 2/6
Xenon Pharmaceuticals is forecast to grow earnings and revenue by 23.7% and 62.7% per annum respectively. EPS is expected to grow by 27.2% per annum. Return on equity is forecast to be -48% in 3 years.
Key information
23.7%
Earnings growth rate
27.2%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 62.7% |
Future return on equity | -48.0% |
Analyst coverage | Good |
Last updated | 10 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 62 | -278 | -243 | -277 | 13 |
12/31/2025 | 9 | -260 | -169 | -249 | 17 |
12/31/2024 | 2 | -220 | -214 | -206 | 17 |
12/31/2023 | N/A | -182 | -151 | -145 | N/A |
9/30/2023 | N/A | -175 | -150 | -143 | N/A |
6/30/2023 | 0 | -164 | -137 | -131 | N/A |
3/31/2023 | 1 | -147 | -119 | -114 | N/A |
12/31/2022 | 9 | -126 | -101 | -98 | N/A |
9/30/2022 | 13 | -113 | -88 | -86 | N/A |
6/30/2022 | 21 | -91 | -73 | -71 | N/A |
3/31/2022 | 23 | -83 | -69 | -67 | N/A |
12/31/2021 | 18 | -81 | -72 | -70 | N/A |
9/30/2021 | 20 | -66 | -64 | -62 | N/A |
6/30/2021 | 18 | -59 | -61 | -58 | N/A |
3/31/2021 | 29 | -37 | -58 | -56 | N/A |
12/31/2020 | 32 | -29 | -51 | -48 | N/A |
9/30/2020 | 30 | -28 | -18 | -15 | N/A |
6/30/2020 | 27 | -28 | -13 | -11 | N/A |
3/31/2020 | 14 | -38 | -11 | -9 | N/A |
12/31/2019 | 7 | -42 | -6 | -5 | N/A |
9/30/2019 | 4 | -39 | -33 | -32 | N/A |
6/30/2019 | N/A | -44 | -39 | -38 | N/A |
3/31/2019 | N/A | -42 | -36 | -35 | N/A |
12/31/2018 | N/A | -34 | -35 | -35 | N/A |
9/30/2018 | 0 | -34 | -35 | -34 | N/A |
6/30/2018 | 0 | -27 | -30 | -29 | N/A |
3/31/2018 | 0 | -27 | -31 | -30 | N/A |
12/31/2017 | 0 | -31 | -29 | -29 | N/A |
9/30/2017 | 1 | -29 | N/A | -27 | N/A |
6/30/2017 | 1 | -29 | N/A | -22 | N/A |
3/31/2017 | 1 | -27 | N/A | -21 | N/A |
12/31/2016 | 2 | -23 | N/A | -20 | N/A |
9/30/2016 | 5 | -21 | N/A | -20 | N/A |
6/30/2016 | 9 | -17 | N/A | -21 | N/A |
3/31/2016 | 12 | -10 | N/A | -17 | N/A |
12/31/2015 | 16 | -16 | N/A | -18 | N/A |
9/30/2015 | 17 | -2 | N/A | -16 | N/A |
6/30/2015 | 26 | 5 | N/A | -5 | N/A |
3/31/2015 | 27 | 4 | N/A | -4 | N/A |
12/31/2014 | 28 | 13 | N/A | 0 | N/A |
9/30/2014 | 29 | 6 | N/A | 1 | N/A |
6/30/2014 | 27 | 4 | N/A | -1 | N/A |
3/31/2014 | 27 | 4 | N/A | -1 | N/A |
12/31/2013 | 27 | 4 | N/A | -3 | N/A |
9/30/2013 | 25 | 0 | N/A | 19 | N/A |
6/30/2013 | 17 | -3 | N/A | 34 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XP0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XP0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XP0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XP0's revenue (62.7% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: XP0's revenue (62.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: XP0 is forecast to be unprofitable in 3 years.